A Phase 2/3 interventional study of QL1706 and Bevacizumab in Hepatocellular Carcinoma, sponsored by Qilu Pharmaceutical Co., Ltd.. Not yet recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-08-04.
Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing Iparomlimab/Tuvonralimab in Carcinoma, Hepatocellular — 14 open to participants now, 14 under way, 1 of them phase 3. Iparomlimab/Tuvonralimab · Carcinoma, Hepatocellular.
Among the 14 studies testing Iparomlimab/Tuvonralimab in Carcinoma, Hepatocellular, this one has the largest planned enrollment, is the only one that started in 2023, is the only one in phase 2/3, reaches primary completion later than 5 of the 13 other live ones, and was the 1st registered.
3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.
Browse Carcinoma, Hepatocellular studies →14 of the 14 studies testing Iparomlimab/Tuvonralimab in Carcinoma, Hepatocellular are open now, in 1 country. Recruiting first, the newest first:
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Sites in China
Ages 18–75
Fudan University · Sites in China
Ages 18–75
Tongji Hospital · Sites in China
Ages 18–75
Nanjing Tianyinshan Hospital · Sites in China
Ages 18+
Hebei Medical University Fourth Hospital · Sites in China
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 9 · Phase 3 1 · Phase 4 1
First in 2023; this study’s year is marked. 1 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 668 is above the median of 54 across 2,620 interventional studies indexed under Carcinoma, Hepatocellular.
Median enrollment 36 across the 14 interventional studies. None of them has completed or been terminated yet.
This tab as a report to print or save as PDF → With an account.
1 of 14 have an industry lead sponsor. The 10 most frequent:
Qilu Pharmaceutical Co., Ltd. is the lead sponsor of 200 studies on the registry; 122 are open to participants now.
Qilu Pharmaceutical Co., Ltd. has 1 study filed under Carcinoma, Hepatocellular — fewer than ten, so there is no comparison to draw.
4 of the studies testing Iparomlimab/Tuvonralimab in Carcinoma, Hepatocellular that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05976568Phase 3Qilu Pharmaceutical Co., Ltd.A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma | 2027-09-01 |
| NCT07115550Huai'an First People's HospitalA Single-center, Single-arm, Phase II Clinical Study of Iparomlimab and Tuvonralimab Injection Combined With Regorafenib in the Treatment of Advanced Second-line or Above Hepatocellular Carcinoma | 2027-08-26 |
| NCT06884982Northern Jiangsu People's HospitalAn Exploratory Clinical Study on Neoadjuvant Treatment of Hepatocellular Carcinoma with QL1706 Combined with Lenvatinib | 2027-09-30 |
| NCT07776080Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyIparomlimab and Tuvonralimab With Lenvatinib, Radiotherapy, and HAIC for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus | 2027-10-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 14 studies testing Iparomlimab/Tuvonralimab in Carcinoma, Hepatocellular, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess the efficacy and safety of QL1706 in combination with bevacizumab and/or chemotherapy versus sintilimab in combination with bevacizumab as first-line treatment in patients with advanced hepatocellular carcinoma.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QL1706 in combination with bevacizumab and chemotherapy
Drug: QL1706 · Drug: Bevacizumab · Drug: Oxaliplatin injection · Drug: Capecitabine
QL1706 in combination with bevacizumab
Drug: QL1706 · Drug: Bevacizumab
QL1706 in combination with chemotherapy
Drug: QL1706 · Drug: Oxaliplatin injection · Drug: Capecitabine
Sintilimab in combination with bevacizumab
Drug: Bevacizumab · Drug: Sintilimab
7.5 mg/kg administered as IV infusion on Day 1 of each 21-day cycle
15 mg/kg administered as IV infusion on Day 1 of each 21-day cycle
85 mg/m2 administered as IV infusion on Day 1 of each 21-day cycle
1000 mg/m2 orally twice daily for 14 days continuous dosing followed by a 7-day break of each 21-day cycle
200 mg administered as IV infusion on Day 1 of each 21-day cycle
Objective Response Rate (ORR) (Phase II)
ORR was assessed by investigators per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1).
Time frame: Up to approximately 4 years
Incidence of Adverse Events (AEs) (Phase II)
An adverse event is any untoward medical occurrence in a subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product.
Time frame: Up to approximately 4 years
Overall Survival (OS) (Phase III)
OS was defined as the time from randomization to death due to any cause.
Time frame: Up to approximately 4 years
Objective Response Rate (ORR)
ORR was assessed by investigators per RECIST 1.1
Time frame: Up to approximately 4 years
Disease Control Rate (DCR)
DCR was assessed by investigators per RECIST 1.1
Time frame: Up to approximately 4 years
Duration of Response (DOR)
DOR was assessed by investigators per RECIST 1.1
Time frame: Up to approximately 4 years
Progression-free Survival (PFS)
PFS was assessed by investigators per RECIST 1.1
Time frame: Up to approximately 4 years
Time to progression (TTP)
TTP was assessed by investigators per RECIST 1.1
Time frame: Up to approximately 4 years
Objective Response Rate (ORR)
ORR was assessed by investigators per mRECIST
Time frame: Up to approximately 4 years
Disease Control Rate (DCR)
DCR was assessed by investigators per mRECIST
Time frame: Up to approximately 4 years
Duration of Response (DOR)
DOR was assessed by investigators per mRECIST
Time frame: Up to approximately 4 years
Progression-free Survival (PFS)
PFS was assessed by investigators per mRECIST
Time frame: Up to approximately 4 years
Time to progression (TTP)
TTP was assessed by investigators per mRECIST
Time frame: Up to approximately 4 years
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Sep 2023; primary completion for Sep 2027, 48 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Iparomlimab/Tuvonralimab · Bevacizumab
Qilu Pharmaceutical Co., Ltd. →